We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
Cap. Flow
-$15.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$25.7M
2
AMGN icon
Amgen
AMGN
+$24.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.6M
4
QURE icon
uniQure
QURE
+$11.2M
5
CNC icon
Centene
CNC
+$11.2M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$77.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$47.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$31.8M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$23.8M
5
A icon
Agilent Technologies
A
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.82%
2 Consumer Staples 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
101
DELISTED
Akero Therapeutics
AKRO
$5.12M 0.2%
225,000
– –
DERM
102
DELISTED
Dermira, Inc.
DERM
$4.95M 0.2%
775,000
– –
NGM
103
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.86M 0.19%
351,100
– –
CGEN icon
104
Compugen
CGEN
$228M
$4.65M 0.19%
1,100,000
– –
CBAY
105
DELISTED
Cymabay Therapeutics
CBAY
$4.61M 0.18%
900,000
– –
NBRV
106
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.6M 0.18%
9,200
+2,800
+44% +$1.58M
CO
107
DELISTED
Global Cord Blood Corporation
CO
$4.48M 0.18%
925,000
– –
CHMA
108
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.46M 0.18%
900,000
+250,000
+38% +$1.42M
GMDA
109
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$4.33M 0.17%
1,000,000
– –
BLUE
110
DELISTED
bluebird bio
BLUE
$4.32M 0.17%
3,628
– –
HCAT icon
111
Health Catalyst
HCAT
$128M
$3.96M 0.16%
+125,000
New +$4.92M
MGNX icon
112
MacroGenics
MGNX
$257M
$3.83M 0.15%
300,000
– –
LJPC
113
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.74M 0.15%
425,000
– –
ICPT
114
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.61M 0.14%
54,400
+4,400
+9% +$295K
ACET icon
115
Adicet Bio
ACET
$74.7M
$3.54M 0.14%
3,571
– –
ARVN icon
116
Arvinas
ARVN
$572M
$3.23M 0.13%
150,000
– –
ACRS icon
117
Aclaris Therapeutics
ACRS
$869M
$3.21M 0.13%
2,974,754
+946,754
+47% +$1.34M
TXG icon
118
10x Genomics
TXG
$6.61B
$3.2M 0.13%
+63,500
New +$3.51M
FPRX
119
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3M 0.12%
775,000
+248,900
+47% +$1.37M
CORV
120
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.4M 0.1%
1,200,000
– –
MYOV
121
DELISTED
Myovant Sciences Ltd.
MYOV
$2.34M 0.09%
450,000
– –
MRSN
122
DELISTED
Mersana Therapeutics
MRSN
$2.21M 0.09%
56,000
– –
PRTK
123
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.94M 0.08%
450,000
– –
ADAP
124
DELISTED
Adaptimmune Therapeutics
ADAP
$1.32M 0.05%
875,000
– –
CRVS icon
125
Corvus Pharmaceuticals
CRVS
$1.17B
$1.2M 0.05%
400,000
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

  • Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
  • Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
  • Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
  • Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
  • Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.